Journal of Vascular Nursing
Volume 21, Issue 1 , Pages 5-16 , March 2003

Treating patients with peripheral arterial disease and claudication

References 

  1. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209–215
  2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  3. Hiatt WR. Morbidity of PAD: medical approaches to claudication. Introduction and overview. In:  Hirsch AT editors. An office-based approach to the diagnosis and treatment of PAD, part IV: management of peripheral arterial disease: moderate claudication. Hillsborough (NJ): Excerpta Medica; 2000;p. 76–87
  4. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997;2:243–251
  5. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221–226
  6. TransAtlantic Inter-Society Consensus TASC Working Group . Management of peripheral arterial disease (PAD). J Vasc Surg. 2000;31(suppl 1):S1–S296
  7. Leng GC, Lee AJ, Fowkes FGR, Whiteman M, Dunbar J, Housley E, et al.  Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–1181
  8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al.  Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  9. Khaira HS, Hanger R, Shearman CP. Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 1996;11:65–69
  10. Ponte E, Cattinelli S. Quality of life in a group of patients with intermittent claudication. Angiology. 1996;47:247–251
  11. Treat-Jacobson D, Halverson SL, Ratchford A, Regensteiner JG, Lindquist R, Hirsch AT. A patient-derived perspective of health-related quality of life in peripheral arterial disease. J Nurs Scholarsh. 2002;34:55–60
  12. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med. 1996;1:60–64
  13. Ingolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol—the Reykjavik study. J Clin Epidemiol. 1994;47:1237–1243
  14. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand. 1982;211:249–256
  15. Hilleman DE. Management of peripheral arterial disease. Am J Health Syst Pharm. 1998;55(suppl 1):S21–S27
  16. Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg. 1991;5:291–304
  17. Powell JT, Greenhalgh RM. Changing the smoking habit and its influence on the management of vascular disease. Acta Chir Scand. 1990;555(suppl):99–103
  18. Lassila R, Seyberth HW, Haapanen A, Schweer H, Koskenvuo M, Laustiola KE. Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking. BMJ. 1988;297:955–957
  19. Beach KW, Brunzell JD, Strandness DE. Prevalence of severe atherosclerosis obliterans in patients with diabetes mellitus. Atherosclerosis. 1982;2:275–280
  20. Joint National Committee . The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446
  21. Fowkes FGR, Dunbar JT, Lee AJ. Risk factor profile of nonsmokers with peripheral arterial disease. Angiology. 1995;46:657–662
  22. Kannel WB, McGee DL. Update on some epidemiological features of intermittent claudication: The Framingham Study. J Am Geriatric Soc. 1985;33:13–18
  23. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: risk profile from the Framingham Study. Circulation. 1997;96:44–49
  24. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb Vasc Biol. 1993;13:1441–1448
  25. Drexel H, Steurer J, Muntwyler J, Meienberg S, Schmid HR, Schneider E, et al.  Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation. 1996;94(Suppl):II199–II205
  26. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472–1479
  27. Mowat BF, Skinner ER, Wilson HM, Leng GC, Fowkes FG, Horrobin D. Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease. Atherosclerosis. 1997;131:161–166
  28. Robinson K. Newer risk factors and peripheral arterial disease. In:  Hirsch AT editors. An office-based approach to the diagnosis and treatment of PAD, part VIII: PAD and risk-factor management. Hillsborough (NJ): Excerpta Medica; 2000;p. 20–25
  29. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, et al.  Prevalence of hyperhomocysteinemia in patients with peripheral arterial disease. Circulation. 1989;79:1180–1188
  30. Creager MA. Medical management of peripheral arterial disease. Cardiol Rev. 2002;9:238–245
  31. Ridker PM, Hennekins CH, Selhub J, Miletich JP, Malinow MR, Stmpfer MJ. Interrelation of hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777–1782
  32. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29:8–19
  33. Towend J, O'Sullivan J, Wilde JT. Hyperhomocysteinemia and vascular disease. Blood Rev. 1998;12:23–24
  34. Regensteiner JG, Hirsch AT. Claudication: the primary symptom of peripheral arterial disease. In:  Hiatt WR,  Hirsch AT,  Regensteiner JG editor. Peripheral arterial disease handbook. Boca Raton (FL): CRC; 2001;p. 95–117
  35. McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med. 1998;158:1357–1364
  36. Dormandy JA, Murray GD. The fate of the claudicant—a prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5:131–133
  37. Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg. 1969;56:676–679
  38. Carter SA. The role of pressure measurements in vascular disease. In:  Bernstein EF editors. Non-invasive diagnostic techniques in vascular disease. St Louis (MO): Mosby; 1985;p. 513–544
  39. Olin JW. Clinical evaluation and office-based detection of peripheral arterial disease. In:  Hirsch AT editors. An office-based approach to the diagnosis and treatment of PAD, part I: the epidemiology and practical detection of PAD. Hillsborough (NJ): Excerpta Medica; 2001;p. 12–19
  40. Jaff MR, Hiatt WR. Clinical and vascular laboratory evaluation of peripheral arterial disease. In:  Hiatt WR,  Hirsch AT,  Regensteiner JG editor. Peripheral arterial disease handbook. Boca Raton (FL): CRC; 2001;p. 81–94
  41. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142–152
  42. McHorney CA, Ware JE, Raczek AE, The MOS. 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263
  43. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med. 1996;1:181–186
  44. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–260
  45. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217–219
  46. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER. Treating tobacco use and dependence.. A clinical practice guideline. Rockville, MD: US Dept of Health and Human Services, Agency for Healthcare Research and Quality;; 2000; AHRQ Publication No. 00-0032
  47. Joseph AM, Norman S, Ferry L, Prochazka AV, Westman EC, Steele BG, et al.  The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798
  48. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al.  A comparison of sustained-release buproprion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  49. Halverson SL, Hirsch AT. Tobacco and peripheral arterial disease: pathogenesis of PAD and the management of tobacco addiction. In:  Hirsch AT editors. An office-based approach to the diagnosis and treatment of peripheral arterial disease, part VIII: PAD and risk-factor management. Hillsborough (NJ): Excerpta Medica; 2001;p. 181–187
  50. UK Prospective Diabetes Study UKPDS Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  51. UK Prospective Diabetes Study UKPDS Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  52. The Diabetes Control , Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  53. The Diabetes Control , Complications Trial Research Group . Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA. 1996;276:1409–1415
  54. Antiplatelet Trialists' Collaboration . Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320–331
  55. Fagher B. Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis: a double-blind study. Angiology. 1994;45:777–788
  56. CAPRIE Steering Committee . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  57. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–364
  58. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  59. Leng GC, Price JF, Jepson RG. Lipid lowering for lower limb atherosclerosis (Cochrane Review). In: The Cochrane library. Oxford, England: Update Software; 2001;p. CD000123
  60. Expert Panel on Detection , Evaluation , Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001;285:2486–2497
  61. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602–609
  62. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975–980
  63. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–115
  64. Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc Med. 1997;2:238–242
  65. Regensteiner JG, Hiatt WR. Exercise rehabilitation for patients with peripheral arterial disease. Exerc Sport Sci Rev. 1995;23:1–24
  66. Current procedural terminology codebook. Chicago (IL): American Medical Association; 2001;
  67. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 1984;56:831–838
  68. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol. 1987;62:2383–2387
  69. Holm J, Dahloff AG, Bjorntorp B, Schersten T. Enzyme studies in muscles of patients with intermittent claudication, effect of training. Scand J Clin Lab Invest. 1973;31(suppl 128):201–205
  70. Hirsch AT, Ekers MA. A comprehensive vascular medical therapeutic approach to peripheral arterial disease: the foundation of effective vascular rehabilitation. In:  Fahey VA editors. Vascular nursing. Philadelphia (PA): WB Saunders; 1999;
  71. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J. 1996;155:1053–1059
  72. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135–146
  73. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678–686
  74. Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14:63–71
  75. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al.  Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–275
  76. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942–1947

☆ Supported by an unrestricted educational grant from Otsuka America Pharmaceuticals Inc, Rockville, MD, and Pharmacia Corp, Peapack, NJ.

☆☆ Address reprint requests to Diane Treat-Jacobson, PhD, RN, University of Minnesota School of Nursing, 6-101 Weaver-Densford Hall, 308 Harvard St SE, Minneapolis, MN 55455.

★ 1062-0303/2003/$30.00 + 0

PII: S1062-0303(03)00003-7

doi: 10.1067/mvn.2003.2

Journal of Vascular Nursing
Volume 21, Issue 1 , Pages 5-16 , March 2003

Article Tools

* Image Usage & Resolution